| Year |
Citation |
Score |
| 2013 |
May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. Plos One. 8: e80060. PMID 24312454 DOI: 10.1371/Journal.Pone.0080060 |
0.564 |
|
| 2011 |
Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatric Blood & Cancer. 56: 239-49. PMID 20922763 DOI: 10.1002/Pbc.22801 |
0.422 |
|
| 2010 |
Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Molecular Cancer Therapeutics. 9: 3289-301. PMID 21159612 DOI: 10.1158/1535-7163.Mct-10-0562 |
0.529 |
|
| 2009 |
Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 505-8. PMID 19418547 DOI: 10.1002/Pbc.21988 |
0.372 |
|
| 2009 |
Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Research. 69: 329-37. PMID 19118018 DOI: 10.1158/0008-5472.Can-08-0613 |
0.314 |
|
| 2008 |
Feng L, Barnhart JR, Seeger RC, Wu L, Keshelava N, Huang SH, Jong A. Cdc6 knockdown inhibits human neuroblastoma cell proliferation. Molecular and Cellular Biochemistry. 311: 189-97. PMID 18259842 DOI: 10.1007/S11010-008-9709-5 |
0.511 |
|
| 2008 |
Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 37-45. PMID 17420992 DOI: 10.1002/Pbc.21214 |
0.445 |
|
| 2007 |
Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP. Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 71: 951-60. PMID 17879237 DOI: 10.1002/Cyto.A.20458 |
0.334 |
|
| 2007 |
Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Journal of the National Cancer Institute. 99: 1107-19. PMID 17623797 DOI: 10.1093/Jnci/Djm044 |
0.57 |
|
| 2007 |
Reynolds CP, Kang MH, Keshelava N, Maurer BJ. Assessing combinations of cytotoxic agents using leukemia cell lines. Current Drug Targets. 8: 765-71. PMID 17584032 DOI: 10.2174/138945007780830845 |
0.468 |
|
| 2007 |
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Research. 67: 3094-105. PMID 17409416 DOI: 10.1158/0008-5472.Can-06-3259 |
0.405 |
|
| 2005 |
Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods in Molecular Medicine. 110: 139-53. PMID 15901933 DOI: 10.1385/1-59259-869-2:139 |
0.336 |
|
| 2005 |
Grigoryan R, Keshelava N, Anderson C, Reynolds CP. In vitro testing of chemosensitivity in physiological hypoxia. Methods in Molecular Medicine. 110: 87-100. PMID 15901930 DOI: 10.1385/1-59259-869-2:087 |
0.377 |
|
| 2005 |
Sheard MA, Wu H, Asgharzadeh S, Keshelava N, Reynolds CP, Ye W, Groshen S, Metelitsa L, Seeger RC. Expression of TRAIL on Activated Human NK Cells Contributes to Cytotoxicity Against Human Neuroblastoma Cell Lines Journal of Immunotherapy. 28: 618. DOI: 10.1097/01.Cji.0000190965.88278.Cd |
0.456 |
|
| 2004 |
Wu H, Metelitsa L, Peng XH, Warsi Z, Mouchess M, Keshelava N, Reynolds CP, Ye W, Groshen S, Gillies S, Moats R, Seeger R. Human Natural Killer Lymphocytes Alone and with an Anti-GD2/IL-2 Immunocytokine Are Cytotoxic for Multidrug Resistant Neuroblastoma Cells Journal of Immunotherapy. 27: S51-S52. DOI: 10.1097/00002371-200411000-00186 |
0.391 |
|
| 2003 |
Keshelava N, Tsao-Wei D, Reynolds CP. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3492-502. PMID 12960142 |
0.425 |
|
| 2003 |
Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Research. 63: 1520-6. PMID 12670899 |
0.32 |
|
| 2001 |
Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. Journal of Pediatric Hematology/Oncology. 23: 500-5. PMID 11878777 DOI: 10.1097/00043426-200111000-00007 |
0.43 |
|
| 2000 |
Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Medical and Pediatric Oncology. 35: 659-62. PMID 11107141 DOI: 10.1002/1096-911X(20001201)35:6<659::Aid-Mpo38>3.0.Co;2-4 |
0.493 |
|
| 2000 |
Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Patrick Reynolds C. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors Medical and Pediatric Oncology. 35: 619-622. PMID 11107131 DOI: 10.1002/1096-911X(20001201)35:6<619::Aid-Mpo28>3.0.Co;2-H |
0.508 |
|
| 2000 |
Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Medical and Pediatric Oncology. 35: 563-8. PMID 11107118 DOI: 10.1002/1096-911X(20001201)35:6<563::Aid-Mpo15>3.0.Co;2-J |
0.456 |
|
| 2000 |
Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines Cancer Chemotherapy and Pharmacology. 45: 1-8. PMID 10647494 DOI: 10.1007/Pl00006736 |
0.548 |
|
| 1998 |
Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. European Journal of Cancer (Oxford, England : 1990). 33: 2002-6. PMID 9516842 DOI: 10.1016/S0959-8049(97)00213-X |
0.503 |
|
| Show low-probability matches. |